Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
February 15 2023 - 4:05PM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company, today announced two
upcoming poster presentations at the Conference on Retroviruses and
Opportunistic Infections (CROI), which will take place February
19-22, 2023 in Seattle, Washington.
Details for the poster presentations are as follows:
Poster Number: 512 Title:
No Dose Adjustments for CYP3A4 Substrates When Co-Administered with
BemnifosbuvirSession: Pharmacokinetics/Pharmacodynamics
of SARS-CoV-2 TherapeuticsPoster Number:
513 Title: Bemnifosbuvir Has Low Potential to
Inhibit P-gp, BCRP, and OATP1B1 Mediated
TransportSession: Pharmacokinetics/Pharmacodynamics
of SARS-CoV-2 TherapeuticsAbout Atea
Pharmaceuticals
Atea is a clinical stage biopharmaceutical company focused on
discovering, developing and commercializing oral therapies to
address the unmet medical needs of patients with severe viral
diseases. Leveraging the Company’s deep understanding of antiviral
drug development, nucleos(t)ide chemistry, biology, biochemistry
and virology, Atea has built a proprietary nucleos(t)ide prodrug
platform to develop novel product candidates to treat single
stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent
cause of severe viral diseases. Atea plans to continue to build its
pipeline of antiviral product candidates by augmenting its
nucleos(t)ide platform with other classes of antivirals that may be
used in combination with its nucleos(t)ide product candidates.
Currently, Atea is focused on the clinical development of
orally-available antiviral agents for difficult-to-treat, severe
viral infections, including severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue
virus and hepatitis C virus (HCV). For more information, please
visit www.ateapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding our expectations surrounding the potential of our product
candidates, including bemnifosbuvir combination product candidates,
and expectations regarding our pipeline, including trial design and
development timelines. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
uncertainty around and costs associated with the clinical
development of bemnifosbuvir as a potential treatment for COVID-19,
bemnifosbuvir and ruzasvir for the potential treatment of HCV and
AT-752 for dengue. These and other important factors discussed
under the caption “Risk Factors” in our Annual Report on Form 10-K
for the year ended December 31, 2021 and our other filings with the
SEC could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management’s
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jul 2024 to Jul 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jul 2023 to Jul 2024